{"id":75751,"date":"2022-07-06T14:45:47","date_gmt":"2022-07-06T12:45:47","guid":{"rendered":"https:\/\/www.pcb.ub.edu\/hallmark-barcelona-science-park-innovation\/"},"modified":"2022-07-25T13:50:46","modified_gmt":"2022-07-25T11:50:46","slug":"hallmark-barcelona-science-park-innovation","status":"publish","type":"post","link":"https:\/\/www.pcb.ub.edu\/en\/hallmark-barcelona-science-park-innovation\/","title":{"rendered":"Hallmark Barcelona Science Park innovation"},"content":{"rendered":"<p><strong>2021 was a key year for companies in the life sciences sector, as is clear in the results published in the Biocat Report. A considerable number of these companies are located at the Barcelona Science Park, an environment where entrepreneurship, academic research, cutting-edge R&amp;D and venture capital find common ground to bring about social and economic development geared towards innovation in health. <\/strong><\/p>\n<p><span data-contrast=\"auto\">The advances in research, funding and market a<strong>c<\/strong>cess made by the companies that comprise the PCB community reaffirm the Park\u2019s role as a catalyst for innovative activity and the transfer of knowledge and technology to society and consolidate its position as a benchmark ecosystem in Europe.<\/span><span data-ccp-props=\"{&quot;201341983&quot;:0,&quot;335551550&quot;:6,&quot;335551620&quot;:6,&quot;335559739&quot;:75,&quot;335559740&quot;:240,&quot;469777462&quot;:[708],&quot;469777927&quot;:[0],&quot;469777928&quot;:[1]}\">\u00a0<\/span><\/p>\n<h3><b><span data-contrast=\"auto\">Financial muscle to advance\u00a0<\/span><\/b><span data-ccp-props=\"{&quot;201341983&quot;:0,&quot;335551550&quot;:6,&quot;335551620&quot;:6,&quot;335559739&quot;:75,&quot;335559740&quot;:240,&quot;469777462&quot;:[708],&quot;469777927&quot;:[0],&quot;469777928&quot;:[1]}\">\u00a0<\/span><\/h3>\n<p><span data-contrast=\"auto\">2021 was a key year for the consolidation of PCB community companies\u2019 ability to attract private investment and other sources of funding. Of the total investment raised last year by startups in the BioRegion of Catalonia, \u20ac238 million according to the <\/span><a href=\"https:\/\/informe.biocat.cat\/\" target=\"_blank\" rel=\"noopener\"><span data-contrast=\"none\">2021 Biocat Report<\/span><\/a><span data-contrast=\"auto\">, over 16% was attracted by companies located at the Barcelona Science Park, with a joint total of \u20ac39 million.<\/span><span data-ccp-props=\"{&quot;201341983&quot;:0,&quot;335551550&quot;:6,&quot;335551620&quot;:6,&quot;335559739&quot;:75,&quot;335559740&quot;:240,&quot;469777462&quot;:[708],&quot;469777927&quot;:[0],&quot;469777928&quot;:[1]}\">\u00a0<\/span><\/p>\n<p><span data-contrast=\"auto\">At the top of the list of deals closed by members of the PCB entrepreneurial community in 2021 is <\/span><b><span data-contrast=\"auto\">InBrain Neuroelectronics<\/span><\/b><span data-contrast=\"auto\">, a spin-off of ICN2 and ICREA that is developing smart graphene-based neuroelectronic therapies to treat brain disorders. This deep-tech firm raised <\/span><a href=\"https:\/\/www.inbrain-neuroelectronics.com\/inbrain-neuroelectronics-raises-over-14M-series-a.html\" target=\"_blank\" rel=\"noopener\"><span data-contrast=\"none\">\u20ac<\/span><span data-contrast=\"none\">14.3 million<\/span><\/a><span data-contrast=\"auto\">, the second-largest round of 2021 in the BioRegion and one of the biggest in the Spanish medtech industry, in an operation led jointly by Asabys Partners and Alta Life Sciences, with CDTI Innvierte and two international investors: Vsquared Ventures and TruVenturo GmbH.\u00a0<\/span><span data-ccp-props=\"{&quot;201341983&quot;:0,&quot;335551550&quot;:6,&quot;335551620&quot;:6,&quot;335559739&quot;:75,&quot;335559740&quot;:240,&quot;469777462&quot;:[708],&quot;469777927&quot;:[0],&quot;469777928&quot;:[1]}\">\u00a0<\/span><\/p>\n<p><span data-contrast=\"auto\">The next on the ranking is <\/span><b><span data-contrast=\"auto\">IMIDomics<\/span><\/b><span data-contrast=\"auto\">, which closed a $16.5-million (about <\/span><a href=\"https:\/\/www.businesswire.com\/news\/home\/20210727005257\/en\/IMIDomicsTM-Closes-16.5-Million-Series-A-Financing-to-Advance-its-Precision-Discovery-Platform-for-Immune-Mediated-Inflammatory-Diseases\" target=\"_blank\" rel=\"noopener\"><span data-contrast=\"none\">\u20ac14 million<\/span><\/a><span data-contrast=\"auto\">) Series A round led by US firm DNS Capital, with pharma corporation Brystol Myers Squibb, The Pritzker Organization and TAO Capital, among other investors. This spin-off of the Vall d\u2019Hebron University Hospital-VHIR focuses on R&amp;D for new drugs to treat immune-mediated inflammatory diseases.<\/span><span data-ccp-props=\"{&quot;201341983&quot;:0,&quot;335551550&quot;:6,&quot;335551620&quot;:6,&quot;335559739&quot;:75,&quot;335559740&quot;:240,&quot;469777462&quot;:[708],&quot;469777927&quot;:[0],&quot;469777928&quot;:[1]}\">\u00a0<\/span><\/p>\n<p><span data-contrast=\"auto\">Other noteworthy operations by companies at the PCB were carried out by <\/span><b><span data-contrast=\"auto\">Nuage Therapeutics<\/span><\/b><span data-contrast=\"auto\">, a spin-off of IRB Barcelona and ICREA <\/span><span data-contrast=\"none\">that began working at the Park in 2021<\/span><span data-contrast=\"auto\"> to discover drugs for \u2018undruggable\u2019 therapeutic targets, which raised \u20ac3.2 million thanks to the <\/span><a href=\"https:\/\/www.pcb.ub.edu\/la-spin-off-de-lirb-barcelona-i-icrea-nuage-therapeutics-arrenca-al-pcb-de-la-ma-dasabys\/\" target=\"_blank\" rel=\"noopener\"><span data-contrast=\"none\">funding contributed by the Asabys Partners Sabadell Asabys fund<\/span><\/a><span data-contrast=\"auto\">. Plus, <\/span><b><span data-contrast=\"auto\">Aelix Therapeutics<\/span><\/b><span data-contrast=\"auto\">, a spin-off of the Hivacat consortium working to develop a therapeutic HIV vaccine, raised <\/span><a href=\"http:\/\/perspectivacdti.es\/el-cdti-invierte-junto-a-caixa-innvierte-start-e-ysios-biofund-ii-innvierte-en-aelix-therapeutics-startup-biotecnologica-que-desarrolla-una-vacuna-terapeutica-contra-el-virus-de-inmunodeficiencia-hum\/\" target=\"_blank\" rel=\"noopener\"><span data-contrast=\"none\">\u20ac1.8<\/span><\/a><span data-contrast=\"auto\"> million from Caixa Innvierte Start, Ysios BioFund II Innvierte and CDTI Innvierte; <\/span><b><span data-contrast=\"auto\">Aptadel Therapeutics<\/span><\/b><span data-contrast=\"auto\">, a preclinical biomedical firm developing a new RNA therapy platform to treat cancer that moved into the PCB in 2021 after closing a seed round for <\/span><a href=\"https:\/\/www.pcb.ub.edu\/aptadel-therapeutics-sinstalla-al-parc-cientific-de-barcelona-i-tanca-una-ronda-de-21-milions-de-dolars\/\" target=\"_blank\" rel=\"noopener\"><span data-contrast=\"none\">\u20ac1.7 million<\/span><\/a><span data-contrast=\"auto\"> ($2.1 million); and <\/span><b><span data-contrast=\"auto\">Pharmacelera<\/span><\/b><span data-contrast=\"auto\">, a deep-tech firm that is developing disruptive computational-chemistry solutions for drug discovery, which closed a <\/span><a href=\"https:\/\/capitalcell.es\/campaign\/pharmacelera\/\" target=\"_blank\" rel=\"noopener\"><span data-contrast=\"none\">\u20ac1-million<\/span><\/a><span data-contrast=\"auto\"> crowd equity campaign with Capital Cell, surpassing their initial target of \u20ac800,000 in just two weeks.<\/span> <span data-contrast=\"auto\">Finally, it is worth noting the <\/span><a href=\"https:\/\/wildcard.eithealth.eu\/2020-wildcards-announced\/\" target=\"_blank\" rel=\"noopener\"><span data-contrast=\"none\">\u20ac1.5 million<\/span><\/a> <b><span data-contrast=\"auto\">MiMark<\/span><\/b><span data-contrast=\"auto\"> was awarded through the EIT Health Wild Card programme for its WomEC project and to advance diagnosis of endometrial cancer.\u00a0<\/span><span data-ccp-props=\"{&quot;201341983&quot;:0,&quot;335551550&quot;:6,&quot;335551620&quot;:6,&quot;335559739&quot;:75,&quot;335559740&quot;:240,&quot;469777462&quot;:[708],&quot;469777927&quot;:[0],&quot;469777928&quot;:[1]}\">\u00a0<\/span><\/p>\n<p><span data-contrast=\"auto\">Seven other companies at the Park secured investments under \u20ac1 million, for a joint total of \u20ac2 million to round out the grand total of \u20ac39 million.<\/span><span data-ccp-props=\"{&quot;201341983&quot;:0,&quot;335551550&quot;:6,&quot;335551620&quot;:6,&quot;335559739&quot;:75,&quot;335559740&quot;:240,&quot;469777462&quot;:[708],&quot;469777927&quot;:[0],&quot;469777928&quot;:[1]}\">\u00a0<\/span><\/p>\n<p><span data-contrast=\"none\">2021 was also the year <\/span><b><span data-contrast=\"none\">Gain Therapeutics<\/span><\/b><span data-contrast=\"auto\">, founded in 2017 by Swiss private investors and the TiVenture fund, <\/span><a href=\"https:\/\/www.gaintherapeutics.com\/investors-media\/news-and-events\/53-newsroom\/press-releases\/2020news\/267-ainherapeuticsnnouncesricingofnitialublicffer20210318040507.html\" target=\"_blank\" rel=\"noopener\"><span data-contrast=\"none\">went public on the Nasdaq<\/span><\/a><span data-contrast=\"auto\">. The biotech firm, which is developing next-generation pharmacological chaperones to treat rare diseases with their proprietary SEE-Tx technology (licensed to Catalan firm Minoryx Therapeutics), has its headquarters in Lugano (Switzerland) and its R&amp;D department at the Barcelona Science Park.<\/span><span data-contrast=\"none\">\u00a0<\/span><span data-ccp-props=\"{&quot;201341983&quot;:0,&quot;335551550&quot;:6,&quot;335551620&quot;:6,&quot;335559739&quot;:0,&quot;335559740&quot;:240}\">\u00a0<\/span><\/p>\n<p><span data-contrast=\"auto\">Another notable operation, coming from public funds, is the <a href=\"https:\/\/www.ciencia.gob.es\/en\/Noticias\/2021\/Octubre\/El-Ministerio-de-Ciencia-e-Innovacion-aprueba-la-financiacion-con-casi-15-millones-de-euros-de-los-ensayos-fase-IIb-III-de-la-vacuna-espanola-de-Hipra.html\" target=\"_blank\" rel=\"noopener\">\u20ac15 million<\/a> loan that the CDTI granted to the biotechnology pharmaceutical company based in Amer (Girona) <\/span><b><span data-contrast=\"auto\">HIPRA<\/span><\/b><span data-contrast=\"auto\"> for the development of its recombinant protein vaccine against Covid-19. The team that the multinational has at its PCB R&amp;D center &#8211; where part of the research necessary for the design, generation and characterization of new vaccine antigens is carried out &#8211; is actively participating in the project. The vaccine is currently under continuous review by the European Medicines Agency, a step prior to marketing authorization. Also, <\/span><b><span data-contrast=\"auto\">GENESIS Biomed<\/span><\/b><span data-contrast=\"auto\">, a biomedical sector consultant specializing in early-stage R&amp;D&amp;i projects, helped in funding 3 rounds worth \u20ac3.8 million in 2021 through its Private Fundraising Service; In addition, its vehicle GENESIS Ventures invest invested \u20ac2.5 million in various startups and spin-offs, of which \u20ac90,000 correspond to last year. The company has created another vehicle to invest during 2022.<\/span><span data-contrast=\"auto\">\u00a0<\/span><span data-ccp-props=\"{&quot;201341983&quot;:0,&quot;335551550&quot;:6,&quot;335551620&quot;:6,&quot;335559739&quot;:75,&quot;335559740&quot;:240,&quot;469777462&quot;:[708],&quot;469777927&quot;:[0],&quot;469777928&quot;:[1]}\">\u00a0<\/span><\/p>\n<p><span data-contrast=\"auto\">A success story in mergers and acquisitions comes from <\/span><b><span data-contrast=\"auto\">Infinitec Activos<\/span><\/b><span data-contrast=\"auto\">, an R&amp;D-based company that commercialises active ingredients and delivery systems for the cosmetics industry and was <\/span><a href=\"https:\/\/www.pcb.ub.edu\/lempresa-alemanya-despecialitats-quimiques-evonik-adquireix-infinitec-activos\/\" target=\"_blank\" rel=\"noopener\"><span data-contrast=\"none\">acquired by Evonik<\/span><\/a><span data-contrast=\"auto\">, a Germany company present in over 100 countries with sales of \u20ac12.2 billion. After the acquisition, the price of which wasn\u2019t made public, the company expanded its facilities at the Park to a total of 400 m\u00b2, investing \u20ac500,000, and increased its staff 50%.\u00a0<\/span><span data-ccp-props=\"{&quot;201341983&quot;:0,&quot;335551550&quot;:6,&quot;335551620&quot;:6,&quot;335559739&quot;:75,&quot;335559740&quot;:240,&quot;469777462&quot;:[708],&quot;469777927&quot;:[0],&quot;469777928&quot;:[1]}\">\u00a0<\/span><\/p>\n<p><span data-contrast=\"auto\">In terms of licences, <\/span><b><span data-contrast=\"auto\">Oncoheroes Biosciences<\/span><\/b><span data-contrast=\"auto\">, a start-up working on new therapies for childhood cancers, licensed the development and commercialisation rights for volasertib to US-based Notable Labs in 2021, holding on to the global licence for paediatric oncology.<\/span><span data-contrast=\"none\">\u202f<\/span><span data-ccp-props=\"{&quot;201341983&quot;:0,&quot;335551550&quot;:6,&quot;335551620&quot;:6,&quot;335559739&quot;:75,&quot;335559740&quot;:240,&quot;469777462&quot;:[708],&quot;469777927&quot;:[0],&quot;469777928&quot;:[1]}\">\u00a0<\/span><\/p>\n<p><span data-contrast=\"auto\">Finally, <\/span><b><span data-contrast=\"auto\">Qiagen<\/span><\/b><span data-contrast=\"auto\"> launched to market its <\/span><a href=\"https:\/\/eur02.safelinks.protection.outlook.com\/?url=https:\/\/www.pcb.ub.edu\/qiagen-amplia-el-menu-de-proves-de-qiastat-dx-amb-una-prova-respiratoria-four-plex-que-diferencia-entre-la-grip-el-vrs-i-el-sars-cov-2\/&amp;data=05|01|Joan.Adan@qiagen.com|d49376b8f14c46c696c208da59cbd923|dc81d03c239c4fd5a96f18a58773c86c|0|0|637921029304520885|Unknown|TWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0=|3000|||&amp;sdata=1VmTotbsEr1vfESG\/Jui2XvtMDxPjRAFK+XgK+OKzZI=&amp;reserved=0\" target=\"_blank\" rel=\"noopener\"><span data-contrast=\"none\">QIAstat-Dx respiratory four-plex panel<\/span><\/a><span data-contrast=\"auto\"> for the QIAstat-Dxtesting system, which identifies whether a patient has a standard seasonal respiratory infection (flu A and B, RSV) or SARS-CoV-2 in just one hour.<\/span><span data-ccp-props=\"{&quot;201341983&quot;:0,&quot;335551550&quot;:6,&quot;335551620&quot;:6,&quot;335559739&quot;:75,&quot;335559740&quot;:240,&quot;469777462&quot;:[708],&quot;469777927&quot;:[0],&quot;469777928&quot;:[1]}\">\u00a0<\/span><\/p>\n<p><span data-contrast=\"none\">\u201cIn life sciences, it takes a long time, even years, and money to convert basic research into new products or services that reach society and have an impact on the health of all of us. However, we have many indicators that show how innovative projects are moving towards this destination, how they attract public and private capital, and successfully pass new preclinical and clinical phases and finally reach market. After 20 years of existence, the PCB has created a community of 3,200 professionals that demonstrates the fulfillment of these achievements, from the most basic research to innovation with new products and services\u201d, explains <\/span><b><span data-contrast=\"none\">Maria Terrades<\/span><\/b><span data-contrast=\"none\">, director of the Science Park of Barcelona.<\/span><span data-ccp-props=\"{&quot;201341983&quot;:0,&quot;335551550&quot;:6,&quot;335551620&quot;:6,&quot;335559739&quot;:75,&quot;335559740&quot;:240,&quot;469777462&quot;:[708],&quot;469777927&quot;:[0],&quot;469777928&quot;:[1]}\">\u00a0<\/span><\/p>\n<h3><b><span data-contrast=\"auto\">Diagnostic solutions and therapies advancing towards patients<\/span><\/b><span data-ccp-props=\"{&quot;201341983&quot;:0,&quot;335551550&quot;:6,&quot;335551620&quot;:6,&quot;335559739&quot;:75,&quot;335559740&quot;:240,&quot;469777462&quot;:[708],&quot;469777927&quot;:[0],&quot;469777928&quot;:[1]}\">\u00a0<\/span><\/h3>\n<p><span data-contrast=\"auto\">Clinical studies are the essential final stage before new drugs, vaccines and diagnostic tools can be approved and launched to market. In advances with new drugs, <\/span><b><span data-contrast=\"auto\">Accure Therapeutics<\/span><\/b><span data-contrast=\"auto\"> kicked off its <\/span><a href=\"https:\/\/www.pcb.ub.edu\/accure-therapeutics-recluta-el-primer-pacient-per-a-lassaig-clinic-en-fase-ii-del-seu-tractament-de-la-neuritis-optica-aguda\/\" target=\"_blank\" rel=\"noopener\"><span data-contrast=\"none\">ACUITY study<\/span><\/a><span data-contrast=\"auto\"> in 2021, a phase II clinical trial on the ACT-01 neuroprotector in patients with acute optic neuritis; femtech start-up <\/span><b><span data-contrast=\"auto\">Oxolife<\/span><\/b><span data-contrast=\"auto\"> started another phase IIa trial, <\/span><a href=\"https:\/\/www.pcb.ub.edu\/oxolife-inicia-un-assaig-clinic-pioner-per-millorar-la-implantacio-embrionaria-i-la-tasa-de-fertilitat-femenina\/\" target=\"_blank\" rel=\"noopener\"><span data-contrast=\"none\">OXOART-2<\/span><\/a><span data-contrast=\"auto\">, to assess the efficacy of its drug OXO-001 that targets embryo implantation to improve pregnancy rates; and <\/span><b><span data-contrast=\"auto\">SOM Biotech<\/span><\/b><span data-contrast=\"auto\"> presented the results of its <\/span><a href=\"https:\/\/sombiotech.com\/som3355-for-chorea-in-huntingtons-disease\/\" target=\"_blank\" rel=\"noopener\"><span data-contrast=\"none\">phase IIa trial on SOM3355<\/span><\/a><span data-contrast=\"auto\">, an innovative treatment for chorea associated with Huntington\u2019s disease that has been granted FDA orphan-drug status and is currently in phase IIb in Europe. This is the company\u2019s second product to reach the clinical phase<\/span><span data-ccp-props=\"{&quot;201341983&quot;:0,&quot;335551550&quot;:6,&quot;335551620&quot;:6,&quot;335559739&quot;:75,&quot;335559740&quot;:240,&quot;469777462&quot;:[708],&quot;469777927&quot;:[0],&quot;469777928&quot;:[1]}\">\u00a0<\/span><\/p>\n<p><span data-contrast=\"auto\">Regarding advances in vaccines, <\/span><b><span data-contrast=\"auto\">Aelix Therapeutics<\/span><\/b><span data-contrast=\"auto\"> announced positive results from its <\/span><a href=\"https:\/\/www.pcb.ub.edu\/aelix-therapeutics-presenta-resultats-positius-de-lassaig-clinic-de-fase-i-iia-de-la-seva-vacuna-terapeutica-contra-el-vih\/\" target=\"_blank\" rel=\"noopener\"><span data-contrast=\"none\">AELIX-002<\/span><\/a><span data-contrast=\"auto\"> trial, a phase I\/IIa clinical study on its therapeutic HIV vaccine.\u00a0<\/span><span data-ccp-props=\"{&quot;201341983&quot;:0,&quot;335551550&quot;:6,&quot;335551620&quot;:6,&quot;335559739&quot;:75,&quot;335559740&quot;:240,&quot;469777462&quot;:[708],&quot;469777927&quot;:[0],&quot;469777928&quot;:[1]}\">\u00a0<\/span><\/p>\n<p><span data-contrast=\"auto\">Finally, in the field of diagnostics, <\/span><b><span data-contrast=\"auto\">GlyCardial Diagnostics<\/span><\/b><span data-contrast=\"auto\"> finished recruiting for the <\/span><a href=\"https:\/\/www.pcb.ub.edu\/glycardial-diagnostics-completa-el-reclutament-de-lassaig-edica-per-validar-seu-dispositiu-de-diagnostic-per-a-la-isquemia-cardiaca\/\" target=\"_blank\" rel=\"noopener\"><span data-contrast=\"none\">EDICA trial<\/span><\/a><span data-contrast=\"auto\">, an international multi-site study that hope to validate its innovative in vitro diagnostic (IVD) technology to detect the Apo J-Glyc protein as a blood biomarker for early diagnosis of myocardial ischemia. <\/span><b><span data-contrast=\"auto\">Qiagen<\/span><\/b><span data-contrast=\"auto\">, for its part, conducted in 2021 clinical trials in European hospitals to obtain CE mark certification for its meningitis detection panel and clinical trials in US hospitals to be able to apply to the FDA for authorization of its gastrointestinal disease testing panel.<\/span><span data-ccp-props=\"{&quot;201341983&quot;:0,&quot;335551550&quot;:6,&quot;335551620&quot;:6,&quot;335559739&quot;:75,&quot;335559740&quot;:240,&quot;469777462&quot;:[708],&quot;469777927&quot;:[0],&quot;469777928&quot;:[1]}\">\u00a0<\/span><\/p>\n<h3><b><span data-contrast=\"auto\">Cutting-edge research<\/span><\/b><span data-ccp-props=\"{&quot;201341983&quot;:0,&quot;335551550&quot;:6,&quot;335551620&quot;:6,&quot;335559739&quot;:75,&quot;335559740&quot;:240,&quot;469777462&quot;:[708],&quot;469777927&quot;:[0],&quot;469777928&quot;:[1]}\">\u00a0<\/span><\/h3>\n<p><span data-contrast=\"none\">In the very early stages, significant advances were made in the preclinical phases, which have not yet begun testing on humans. <\/span><span data-contrast=\"auto\">In collaboration with US company Galyan Bio, <\/span><b><span data-contrast=\"auto\">Chemotargets<\/span><\/b><span data-contrast=\"auto\"> used its AI-based de novo drug design methods to create the <\/span><a href=\"https:\/\/www.pcb.ub.edu\/dissenyen-el-primer-farmac-amb-intelligencia-artificial-per-a-la-malaltia-de-huntington\/\" target=\"_blank\" rel=\"noopener\"><span data-contrast=\"none\">first clinical candidate for Huntington\u2019s disease designed using artificial intelligence<\/span><\/a><span data-contrast=\"auto\">; start-up <\/span><b><span data-contrast=\"auto\">Moirai Biodesign<\/span><\/b><span data-contrast=\"auto\"> launched <\/span><a href=\"https:\/\/www.pcb.ub.edu\/moirai-biodesign-desenvolupa-un-innovador-software-per-al-disseny-darn-sintetic\/\" target=\"_blank\" rel=\"noopener\"><span data-contrast=\"none\">MoiRNAiFold<\/span><\/a><span data-contrast=\"auto\">, advanced software to design complex RNA molecules; <\/span><b><span data-contrast=\"auto\">Connecta Therapeutics<\/span><\/b><span data-contrast=\"auto\"> finished the regulatory preclinical toxicology phase for its <\/span><a href=\"https:\/\/www.pcb.ub.edu\/el-farmac-de-connecta-therapeutics-per-a-la-sindrome-x-fragil-rep-la-designacio-de-medicament-orfe-de-lema\/\" target=\"_blank\" rel=\"noopener\"><span data-contrast=\"none\">drug CTH120<\/span><\/a><span data-contrast=\"auto\">, which was granted EMA orphan-drug status to treat Fragile-X syndrome (FXS); and <\/span><b><span data-contrast=\"auto\">Oxolife<\/span><\/b><span data-contrast=\"auto\"> also reached the final phases of preclinical development with its <\/span><a href=\"https:\/\/oxolife.com\/es\/tecnologia\/\" target=\"_blank\" rel=\"noopener\"><span data-contrast=\"none\">drug OXO-001<\/span><\/a><span data-contrast=\"auto\"> to treat infertility associated with Polycystic Ovary Syndrome (PCOS). Also in women\u2019s health, femtech start-up <\/span><b><span data-contrast=\"auto\">MiMark<\/span><\/b><span data-contrast=\"auto\"> has developed <\/span><a href=\"https:\/\/www.mimark.es\/#solution\" target=\"_blank\" rel=\"noopener\"><span data-contrast=\"none\">WomEC<\/span><\/a><span data-contrast=\"auto\">, a minimally invasive in vitro molecular diagnostic test for endometrial cancer, now in the prototype phase; and researchers at the <\/span><b><span data-contrast=\"auto\">Eugin<\/span><\/b><span data-contrast=\"auto\"> basic research lab revealed that <\/span><a href=\"https:\/\/www.pcb.ub.edu\/la-qualitat-dels-ovuls-esta-directament-relacionada-amb-lactivitat-mitocondrial\/\" target=\"_blank\" rel=\"noopener\"><span data-contrast=\"none\">egg quality is related to cell mitochondrial activity<\/span><\/a><span data-contrast=\"auto\">, <\/span><span data-contrast=\"none\">an advance that opens up a new path for addressing female fertility issues<\/span><span data-contrast=\"auto\">.<\/span><span data-ccp-props=\"{&quot;201341983&quot;:0,&quot;335551550&quot;:6,&quot;335551620&quot;:6,&quot;335559739&quot;:75,&quot;335559740&quot;:240,&quot;469777462&quot;:[708],&quot;469777927&quot;:[0],&quot;469777928&quot;:[1]}\">\u00a0<\/span><\/p>\n<p><span data-contrast=\"auto\">In children\u2019s health, the <\/span><b><span data-contrast=\"auto\">Laboratoris Ordesa<\/span><\/b><span data-contrast=\"auto\"> R&amp;D centre carried out several studies to validate the capacity of the <\/span><a href=\"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmicb.2021.642549\/full\" target=\"_blank\" rel=\"noopener\"><span data-contrast=\"none\">probiotics and prebiotics used in their baby formula to improve immune and gastrointestinal function in infants.<\/span><\/a><span data-contrast=\"auto\"> Finally, also in 2021, Thai company <\/span><b><span data-contrast=\"auto\">SeriTech<\/span><\/b><span data-contrast=\"auto\"> began an ambitious R&amp;D programme at the Park to promote the medicinal applications of silk proteins and accelerate introduction into the pharmaceutical and cosmetics industries of an <\/span><a href=\"https:\/\/www.pcb.ub.edu\/seritech-microvectors\/\" target=\"_blank\" rel=\"noopener\"><span data-contrast=\"none\">innovative transdermal delivery method for active ingredients<\/span><\/a><span data-contrast=\"auto\">.<\/span><span data-ccp-props=\"{&quot;201341983&quot;:0,&quot;335551550&quot;:6,&quot;335551620&quot;:6,&quot;335559739&quot;:75,&quot;335559740&quot;:240,&quot;469777462&quot;:[708],&quot;469777927&quot;:[0],&quot;469777928&quot;:[1]}\">\u00a0<\/span><\/p>\n<h3><b><span data-contrast=\"auto\">New science and technical capacities\u00a0<\/span><\/b><span data-ccp-props=\"{&quot;201341983&quot;:0,&quot;335551550&quot;:6,&quot;335551620&quot;:6,&quot;335559739&quot;:75,&quot;335559740&quot;:240,&quot;469777462&quot;:[708],&quot;469777927&quot;:[0],&quot;469777928&quot;:[1]}\">\u00a0<\/span><\/h3>\n<p><span data-contrast=\"auto\">The Contract Research Organisations (CRO) located at the PCB remain strategic partners for biotechnology and pharmaceutical companies in the sector. In 2021, <\/span><b><span data-contrast=\"auto\">Enantia<\/span><\/b><span data-contrast=\"auto\"> launched a <\/span><a href=\"https:\/\/www.pcb.ub.edu\/enantia-posa-en-marxa-un-kilo-lab-en-el-parc-cientific-de-barcelona-per-a-lescalat-de-processos-quimics\/\" target=\"_blank\" rel=\"noopener\"><span data-contrast=\"none\">Kilo Lab<\/span><\/a><span data-contrast=\"auto\"> for development, scale-up and production of key intermediates and preclinical compounds; and <\/span><b><span data-contrast=\"auto\">Bioingenium<\/span><\/b><span data-contrast=\"auto\">, which specialises in the development of bioprocesses and production of therapeutic recombinant proteins, <\/span><a href=\"https:\/\/www.pcb.ub.edu\/bioingenium-amplia-les-seves-installacions-drd-al-parc-cientific-de-barcelona\/\" target=\"_blank\" rel=\"noopener\"><span data-contrast=\"none\">expanded its R&amp;D facilities at the Park<\/span><\/a><span data-contrast=\"auto\"> and acquired new protein fermentation and purification equipment to boost its capacity. <\/span><b><span data-contrast=\"auto\">Dan*na<\/span><\/b><span data-contrast=\"auto\"> launched a pilot plant to scale up production of bioplastics and biomaterials to industrial levels for the biomedical and biotechnology sector.<\/span> <span data-contrast=\"auto\">This start-up is among the <\/span><a href=\"https:\/\/www.startus-insights.com\/innovators-guide\/discover-5-top-startups-developing-sustainable-plastics\/\" target=\"_blank\" rel=\"noopener\"><span data-contrast=\"none\">top 5 in the world<\/span><\/a><span data-contrast=\"auto\"> developing sustainable plastics according to StartUs Insights and was ranked among the <\/span><a href=\"https:\/\/www.emprendedores.es\/casos-de-exito\/lista-emprendedores-startups-espanolas-mas-innovadoras-2021\/\" target=\"_blank\" rel=\"noopener\"><span data-contrast=\"none\">50 most innovative Spanish start-ups in 2021<\/span><\/a><span data-contrast=\"auto\"> by Emprendedores magazine.<\/span><span data-contrast=\"none\">\u202f<\/span><span data-ccp-props=\"{&quot;201341983&quot;:0,&quot;335551550&quot;:6,&quot;335551620&quot;:6,&quot;335559739&quot;:0,&quot;335559740&quot;:240}\">\u00a0<\/span><\/p>\n<p><span data-contrast=\"auto\">For its part, <\/span><b><span data-contrast=\"auto\">Farmaprojects<\/span><\/b><span data-contrast=\"auto\"> opened a <\/span><a href=\"https:\/\/www.pcb.ub.edu\/empresa\/farmaprojects\/\" target=\"_blank\" rel=\"noopener\"><span data-contrast=\"none\">GMP-certified lab<\/span><\/a> <span data-contrast=\"none\">to import and release drugs in the European Union<\/span><span data-contrast=\"auto\">; and <\/span><b><span data-contrast=\"auto\">Solitek<\/span><\/b><span data-contrast=\"auto\">, a CRO <\/span><a href=\"https:\/\/www.pcb.ub.edu\/solitek-un-innovador-proveidor-de-serveis-destat-solid-sinstalla-al-parc-cientific-de-barcelona\/\" target=\"_blank\" rel=\"noopener\"><span data-contrast=\"none\">providing solid-state development services<\/span><\/a><span data-contrast=\"auto\"> for pharmaceutical and biotechnology companies, <\/span><a href=\"https:\/\/www.pcb.ub.edu\/solitek-un-innovador-proveidor-de-serveis-destat-solid-sinstalla-al-parc-cientific-de-barcelona\/\" target=\"_blank\" rel=\"noopener\"><span data-contrast=\"auto\">also started activity at the Park last year<\/span><\/a><span data-contrast=\"auto\">.\u00a0<\/span><span data-ccp-props=\"{&quot;201341983&quot;:0,&quot;335551550&quot;:6,&quot;335551620&quot;:6,&quot;335559739&quot;:75,&quot;335559740&quot;:240,&quot;469777462&quot;:[708],&quot;469777927&quot;:[0],&quot;469777928&quot;:[1]}\">\u00a0<\/span><\/p>\n<p><span data-contrast=\"auto\">Finally, it is worth noting <\/span><b><span data-contrast=\"auto\">Leanbio<\/span><\/b><span data-contrast=\"auto\">\u2019s participation in the European <\/span><a href=\"https:\/\/www.pcb.ub.edu\/accelerar-el-desenvolupament-de-nous-farmacs-basats-en-la-nanotecnologia\/\" target=\"_blank\" rel=\"noopener\"><span data-contrast=\"none\">Phoenix<\/span><\/a><span data-contrast=\"auto\"> project to promote new nanotechnology-based drugs, with a budget of \u20ac14.5 million through the Horizon 2020 programme; and the collaboration between <\/span><b><span data-contrast=\"auto\">Cytes Biotechnologies<\/span><\/b><span data-contrast=\"auto\"> and French firm CTIBiotech on the <\/span><a href=\"https:\/\/www.pcb.ub.edu\/cytes-biotechnologies-i-ctibiotech-inicien-el-projecte-hepnalysi\/\" target=\"_blank\" rel=\"noopener\"><span data-contrast=\"none\">Hepnalysis<\/span><\/a><span data-contrast=\"auto\"> project that is working to produce 3D bioprinted human liver models.<\/span><b><span data-contrast=\"auto\">\u202f<\/span><\/b><span data-ccp-props=\"{&quot;201341983&quot;:0,&quot;335551550&quot;:6,&quot;335551620&quot;:6,&quot;335559739&quot;:0,&quot;335559740&quot;:240}\">\u00a0<\/span><\/p>\n<p><span data-ccp-props=\"{&quot;201341983&quot;:0,&quot;335551550&quot;:6,&quot;335551620&quot;:6,&quot;335559739&quot;:0,&quot;335559740&quot;:240}\">\u00a0<\/span><\/p>\n","protected":false},"excerpt":{"rendered":"<p>2021 was a key year for companies in the life sciences sector, as is clear in the results published in the Biocat Report. A considerable number of these companies are&#8230;<\/p>\n","protected":false},"author":1,"featured_media":75731,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"footnotes":""},"categories":[38],"tags":[],"class_list":["post-75751","post","type-post","status-publish","format-standard","has-post-thumbnail","category-pcb-en"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.7 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Hallmark Barcelona Science Park innovation - Parc Cient\u00edfic de Barcelona<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.pcb.ub.edu\/en\/hallmark-barcelona-science-park-innovation\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Hallmark Barcelona Science Park innovation - Parc Cient\u00edfic de Barcelona\" \/>\n<meta property=\"og:description\" content=\"2021 was a key year for companies in the life sciences sector, as is clear in the results published in the Biocat Report. A considerable number of these companies are...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.pcb.ub.edu\/en\/hallmark-barcelona-science-park-innovation\/\" \/>\n<meta property=\"og:site_name\" content=\"Parc Cient\u00edfic de Barcelona\" \/>\n<meta property=\"article:published_time\" content=\"2022-07-06T12:45:47+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2022-07-25T11:50:46+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2022\/07\/noti-1.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"900\" \/>\n\t<meta property=\"og:image:height\" content=\"330\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"adminpcb\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"adminpcb\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"8 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/hallmark-barcelona-science-park-innovation\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/hallmark-barcelona-science-park-innovation\\\/\"},\"author\":{\"name\":\"adminpcb\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/#\\\/schema\\\/person\\\/d13cab05cd0a75b17fddca8496481021\"},\"headline\":\"Hallmark Barcelona Science Park innovation\",\"datePublished\":\"2022-07-06T12:45:47+00:00\",\"dateModified\":\"2022-07-25T11:50:46+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/hallmark-barcelona-science-park-innovation\\\/\"},\"wordCount\":1689,\"image\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/hallmark-barcelona-science-park-innovation\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.pcb.ub.edu\\\/wp-content\\\/uploads\\\/2022\\\/07\\\/noti-1.jpg\",\"articleSection\":[\"PCB\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/hallmark-barcelona-science-park-innovation\\\/\",\"url\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/hallmark-barcelona-science-park-innovation\\\/\",\"name\":\"Hallmark Barcelona Science Park innovation - Parc Cient\u00edfic de Barcelona\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/hallmark-barcelona-science-park-innovation\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/hallmark-barcelona-science-park-innovation\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.pcb.ub.edu\\\/wp-content\\\/uploads\\\/2022\\\/07\\\/noti-1.jpg\",\"datePublished\":\"2022-07-06T12:45:47+00:00\",\"dateModified\":\"2022-07-25T11:50:46+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/#\\\/schema\\\/person\\\/d13cab05cd0a75b17fddca8496481021\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/hallmark-barcelona-science-park-innovation\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/hallmark-barcelona-science-park-innovation\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/hallmark-barcelona-science-park-innovation\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.pcb.ub.edu\\\/wp-content\\\/uploads\\\/2022\\\/07\\\/noti-1.jpg\",\"contentUrl\":\"https:\\\/\\\/www.pcb.ub.edu\\\/wp-content\\\/uploads\\\/2022\\\/07\\\/noti-1.jpg\",\"width\":900,\"height\":330},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/hallmark-barcelona-science-park-innovation\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Hallmark Barcelona Science Park innovation\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/#website\",\"url\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/\",\"name\":\"Parc Cient\u00edfic de Barcelona\",\"description\":\"Universitat de Barcelona\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/#\\\/schema\\\/person\\\/d13cab05cd0a75b17fddca8496481021\",\"name\":\"adminpcb\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/41ad0fab4bb3bf5348b0af9612159cfd93173a57bbca98fecb50fa6f3ab97d28?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/41ad0fab4bb3bf5348b0af9612159cfd93173a57bbca98fecb50fa6f3ab97d28?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/41ad0fab4bb3bf5348b0af9612159cfd93173a57bbca98fecb50fa6f3ab97d28?s=96&d=mm&r=g\",\"caption\":\"adminpcb\"},\"url\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/author\\\/adminpcb\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Hallmark Barcelona Science Park innovation - Parc Cient\u00edfic de Barcelona","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.pcb.ub.edu\/en\/hallmark-barcelona-science-park-innovation\/","og_locale":"en_US","og_type":"article","og_title":"Hallmark Barcelona Science Park innovation - Parc Cient\u00edfic de Barcelona","og_description":"2021 was a key year for companies in the life sciences sector, as is clear in the results published in the Biocat Report. A considerable number of these companies are...","og_url":"https:\/\/www.pcb.ub.edu\/en\/hallmark-barcelona-science-park-innovation\/","og_site_name":"Parc Cient\u00edfic de Barcelona","article_published_time":"2022-07-06T12:45:47+00:00","article_modified_time":"2022-07-25T11:50:46+00:00","og_image":[{"width":900,"height":330,"url":"https:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2022\/07\/noti-1.jpg","type":"image\/jpeg"}],"author":"adminpcb","twitter_card":"summary_large_image","twitter_misc":{"Written by":"adminpcb","Est. reading time":"8 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.pcb.ub.edu\/en\/hallmark-barcelona-science-park-innovation\/#article","isPartOf":{"@id":"https:\/\/www.pcb.ub.edu\/en\/hallmark-barcelona-science-park-innovation\/"},"author":{"name":"adminpcb","@id":"https:\/\/www.pcb.ub.edu\/es\/#\/schema\/person\/d13cab05cd0a75b17fddca8496481021"},"headline":"Hallmark Barcelona Science Park innovation","datePublished":"2022-07-06T12:45:47+00:00","dateModified":"2022-07-25T11:50:46+00:00","mainEntityOfPage":{"@id":"https:\/\/www.pcb.ub.edu\/en\/hallmark-barcelona-science-park-innovation\/"},"wordCount":1689,"image":{"@id":"https:\/\/www.pcb.ub.edu\/en\/hallmark-barcelona-science-park-innovation\/#primaryimage"},"thumbnailUrl":"https:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2022\/07\/noti-1.jpg","articleSection":["PCB"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.pcb.ub.edu\/en\/hallmark-barcelona-science-park-innovation\/","url":"https:\/\/www.pcb.ub.edu\/en\/hallmark-barcelona-science-park-innovation\/","name":"Hallmark Barcelona Science Park innovation - Parc Cient\u00edfic de Barcelona","isPartOf":{"@id":"https:\/\/www.pcb.ub.edu\/es\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.pcb.ub.edu\/en\/hallmark-barcelona-science-park-innovation\/#primaryimage"},"image":{"@id":"https:\/\/www.pcb.ub.edu\/en\/hallmark-barcelona-science-park-innovation\/#primaryimage"},"thumbnailUrl":"https:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2022\/07\/noti-1.jpg","datePublished":"2022-07-06T12:45:47+00:00","dateModified":"2022-07-25T11:50:46+00:00","author":{"@id":"https:\/\/www.pcb.ub.edu\/es\/#\/schema\/person\/d13cab05cd0a75b17fddca8496481021"},"breadcrumb":{"@id":"https:\/\/www.pcb.ub.edu\/en\/hallmark-barcelona-science-park-innovation\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.pcb.ub.edu\/en\/hallmark-barcelona-science-park-innovation\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.pcb.ub.edu\/en\/hallmark-barcelona-science-park-innovation\/#primaryimage","url":"https:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2022\/07\/noti-1.jpg","contentUrl":"https:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2022\/07\/noti-1.jpg","width":900,"height":330},{"@type":"BreadcrumbList","@id":"https:\/\/www.pcb.ub.edu\/en\/hallmark-barcelona-science-park-innovation\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.pcb.ub.edu\/en\/"},{"@type":"ListItem","position":2,"name":"Hallmark Barcelona Science Park innovation"}]},{"@type":"WebSite","@id":"https:\/\/www.pcb.ub.edu\/es\/#website","url":"https:\/\/www.pcb.ub.edu\/es\/","name":"Parc Cient\u00edfic de Barcelona","description":"Universitat de Barcelona","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.pcb.ub.edu\/es\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.pcb.ub.edu\/es\/#\/schema\/person\/d13cab05cd0a75b17fddca8496481021","name":"adminpcb","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/41ad0fab4bb3bf5348b0af9612159cfd93173a57bbca98fecb50fa6f3ab97d28?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/41ad0fab4bb3bf5348b0af9612159cfd93173a57bbca98fecb50fa6f3ab97d28?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/41ad0fab4bb3bf5348b0af9612159cfd93173a57bbca98fecb50fa6f3ab97d28?s=96&d=mm&r=g","caption":"adminpcb"},"url":"https:\/\/www.pcb.ub.edu\/en\/author\/adminpcb\/"}]}},"_links":{"self":[{"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/posts\/75751","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/comments?post=75751"}],"version-history":[{"count":8,"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/posts\/75751\/revisions"}],"predecessor-version":[{"id":75820,"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/posts\/75751\/revisions\/75820"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/media\/75731"}],"wp:attachment":[{"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/media?parent=75751"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/categories?post=75751"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/tags?post=75751"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}